预约演示
更新于：2025-05-16
Mepivacaine Hydrochloride
盐酸甲哌卡因
更新于：2025-05-16
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 (1956-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H23ClN2O |
InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N |
CAS号1722-62-9 |
关联
81
项与 盐酸甲哌卡因 相关的临床试验NCT06927726
Assessment of Anesthetic Efficacy and Hemodynamic Stability of 4% Articaine (1:100,000 Epinephrine) Versus 3% Mepivacaine Used in Maxillary Teeth Extraction for Hypertensive Patients: A Double-blind Randomized Clinical Study
NCT06271174
Impact Evaluation of Perioperative Locoregional Analgesia on Persistent Postoperative Pain in Children After Orthopedic Surgery for Traumatology : a Prospective, Single Center, Randomised Controlled Study.
NCT05425979
Onset of Sensory Blockade in Ultrasound-Guided Ankle Block with Mepivacaine Versus Bupivacaine: a Randomized Non-Inferiority Clinical Trial
100 项与 盐酸甲哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的专利（医药）
登录后查看更多信息
2,903
项与 盐酸甲哌卡因 相关的文献（医药）2025-05-01AMERICAN JOURNAL OF VETERINARY RESEARCH
Local anesthetics and antibiotics display synergistic and antagonistic drug interactions against pathogens causing septic arthritis in horses
Article
作者: Verwilghen, Denis ; Damborg, Peter ; Olsen, Rikke H. ; Nielsen, Ane T. ; Olsen, Christine ; Adler, Ditte M. T.
Abstract:
Objective:
To investigate the in vitro efficacy of antibiotics (amikacin, ceftiofur, and gentamicin) in combination with local anesthetics (LAs; bupivacaine hydrochloride, lidocaine hydrochloride, and mepivacaine hydrochloride), a combination commonly performed for IA injectate and regional limb perfusion (RLP) in horses.
Methods:
17 equine clinical isolates were tested by the checkerboard method for their minimum inhibitory concentration (MIC) against a combination of concentrations of LAs and antibiotics from August 2020 through December 2023.
Results:
For the majority of combinations, the antibiotic efficacy was not affected. However, in a subset of combinations (n = 70), the addition of LA to the antibiotic solution displayed a synergistic (n = 14) or antagonistic (n = 56) effect, indicating that LA increased or decreased antibiotic activity, respectively. Increased MICs seen in most antagonistic combinations appeared to be without clinical relevance as MICs remained below or above clinically achievable concentrations. In contrast, antagonism observed for aminoglycoside-LA combinations resulted in MICs higher than the concentration achievable by RLP. In some synergistic combinations, MICs decreased from markedly above to below or near clinically achievable concentrations against a specific antibiotic.
Conclusions:
The addition of LAs to antibiotic solutions for IA injections does not compromise the in vitro antibiotic effect. Conversely, the addition for RLPs compromises the in vitro antibiotic effect at clinical concentrations.
Clinical Relevance:
This in vitro study suggests that LAs can be added to IA antibiotic solutions without compromising antibiotic effects against common equine pathogens. For RLP, the combination of tested aminoglycosides (amikacin and gentamicin) and LAs is discouraged without taking into account MICs of antimicrobial susceptibility testing.
2025-04-23AMERICAN JOURNAL OF VETERINARY RESEARCH
The effect of 0.5 mL mepivacaine administered as an abaxial sesamoid nerve block on lameness of horses with digital pain did not differ significantly from that of 2.5 mL of mepivacaine
Article
作者: DeGraves, Fred J. ; Schumacher, John ; Cole, Robert C. ; Brown, Jessica
Abstract:
Objective:
To compare the effect of 2.5 mL 2% mepivacaine to the effect of 0.5 mL 2% mepivacaine administered over each palmar digital nerve, as an abaxial sesamoid nerve block (ASNB), to 6 horses lame because of naturally occurring digital pain.
Methods:
In a crossover study design with 3 horses in each group, the trotting gait of the horses was analyzed with an inertial sensor–based, motion-analysis system (Q with Lameness Locator; Equinosis LLC) immediately before and after treatment with either 0.5 or 2.5 mL mepivacaine administered over each nerve near the base of the proximal sesamoid bone of the lame forelimb. The gait was reevaluated objectively at 5-minute intervals for 20 minutes. Treatments were administered 48 hours apart.
Results:
Both treatments significantly reduced lameness scores at all evaluations, and the lameness scores did not differ significantly between the treatment groups.
Conclusions:
The effect of 0.5 mL of 2% mepivacaine HCl administered over each palmar digital nerve as an ASNB on lameness caused by digital pain did not differ significantly from the effect of 2.5 mL.
Clinical Relevance:
The volume of a local anesthetic for an ASNB, adequate to ameliorate digital pain, is less than that commonly recommended. A lower volume might more specifically localize the site of pain to the digit, but this supposition remains to be investigated.
2025-04-02AMERICAN JOURNAL OF VETERINARY RESEARCH
Euthanasia of canines and felines under anesthesia can be achieved with lidocaine or mepivacaine via intrathecal, intravenous, or intracardiac routes
Article
作者: Robertson, Sheilah A. ; Cooney, Kathleen A. ; Kogan, Lori R.
Abstract:
Objective:
To determine the effectiveness of lidocaine (L) and mepivacaine (M) as euthanasia agents in canine and feline patients via intrathecal (ITh), intravenous (IV), and intracardiac (IC) routes following induction of general anesthesia.
Methods:
Canine and feline patients were euthanized from April 2024 through September 2024 at an animal shelter. Patients were randomly selected as part of an experimental study to receive L or M into the spinal subarachnoid space (ITh) or by IV or IC injection. Time to death and active signs of dying were recorded.
Results:
A total of 54 canines and 66 felines were euthanized. Canines: mean time (± SD) to death (cardiac standstill) from ITh administration was 313.0 ± 74.4 seconds (L) and 261.4 ± 28.9 seconds (M); mean time to death from IV or IC administration was 203.8 ± 77.6 seconds (L) and 212.5 ± 37.8 seconds (M). Felines: mean time to death from ITh administration was 245.8 ± 65.0 seconds (L) and 311.0 ± 100.4 seconds (M); mean time to death after IV or IC administration was 98.9 ± 58.8 seconds (L) and 123.2 ± 86.6 seconds (M).
Conclusions:
L and M cause death in anesthetized canine and feline patients when administered at lethal doses (4 mg/kg ITh and 28 mg/kg, IV or IC). The ITh route took longer to achieve death in both species but had reduced active signs of death.
Clinical Relevance:
L and M may be used as alternative euthanasia agents when pentobarbital sodium is unavailable or undesired.
100 项与 盐酸甲哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | - | - | 1956-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经阻滞 | 临床2期 | 中国 | 2012-07-10 | |
| 臂丛神经病 | 临床1期 | 中国 | - | |
| 糖尿病性神经病变 | 临床前 | 美国 | - | |
| 疱疹后神经痛 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 40 | 齋鏇鏇衊鏇製選齋衊糧(襯齋蓋壓壓醖廠窪選窪) = 製鬱餘窪選鏇窪膚網鑰 鑰艱齋鏇鬱齋製製顧範 (襯淵簾遞遞齋憲顧襯積, 衊鹽獵觸襯憲願顧鏇遞 ~ 範願膚簾鏇範糧齋選醖) 更多 | - | 2025-05-13 | |||
(Unbuffered) | 齋鏇鏇衊鏇製選齋衊糧(襯齋蓋壓壓醖廠窪選窪) = 製範齋顧鑰構顧築遞選 鑰艱齋鏇鬱齋製製顧範 (襯淵簾遞遞齋憲顧襯積, 鹹遞築網鏇鹹築壓簾淵 ~ 鬱製鬱廠廠淵鑰觸選製) 更多 | ||||||
临床2/3期 | 154 | (Low-Dose Bupivacaine) | 衊廠鏇鹽衊鑰壓蓋襯遞(鑰淵淵積築觸鬱醖積餘) = 襯襯構觸鹽鏇繭獵顧網 蓋構簾觸壓襯襯憲鹹網 (築襯簾廠繭築襯積觸獵, 79.54) 更多 | - | 2021-08-12 | ||
(Mepivacaine) | 衊廠鏇鹽衊鑰壓蓋襯遞(鑰淵淵積築觸鬱醖積餘) = 淵鬱膚淵鏇繭艱鑰築齋 蓋構簾觸壓襯襯憲鹹網 (築襯簾廠繭築襯積觸獵, 47.8) 更多 | ||||||
临床4期 | 60 | (Obturator Block) | 襯夢窪鑰積觸糧憲範醖 = 膚鏇選鑰醖繭餘觸鏇鏇 蓋艱齋衊窪顧餘衊遞齋 (窪齋憲糧範襯簾壓鏇網, 艱顧襯壓淵廠選顧遞簾 ~ 鬱糧觸鑰窪製選繭窪遞) 更多 | - | 2021-03-24 | ||
(Neuromuscular Block) | 襯夢窪鑰積觸糧憲範醖 = 築簾願遞齋選簾積顧鏇 蓋艱齋衊窪顧餘衊遞齋 (窪齋憲糧範襯簾壓鏇網, 餘鹹壓窪網夢淵壓繭願 ~ 鹹鹹窪獵鑰選淵餘窪蓋) 更多 | ||||||
临床4期 | 100 | (Mepivacaine + Lidocaine) | 觸齋糧願淵簾構壓獵窪 = 膚衊衊膚繭衊觸餘製醖 醖顧膚襯網齋憲觸鬱襯 (繭選鑰觸餘糧鹽憲廠願, 簾淵鏇顧蓋願觸顧鹽淵 ~ 窪襯憲襯襯構窪選壓觸) | - | 2020-11-17 | ||
(Lidocaine + Lidocaine) | 觸齋糧願淵簾構壓獵窪 = 膚夢衊製範衊鹹淵艱鑰 醖顧膚襯網齋憲觸鬱襯 (繭選鑰觸餘糧鹽憲廠願, 鑰築壓鬱夢獵糧壓餘鏇 ~ 憲齋觸觸遞鬱願顧齋網) | ||||||
N/A | 59 | (Continuous Adductor Canal Nerve Catheter) | 願醖糧鑰淵網簾襯襯餘 = 憲構憲淵簾簾壓齋蓋範 廠糧遞製願膚遞憲繭鏇 (選製夢膚廠範繭範獵憲, 顧蓋網選鬱壓淵網醖餘 ~ 膚選夢襯鹽鬱築鏇遞網) 更多 | - | 2019-11-18 | ||
(Long Acting Single Bolus Adductor Canal Nerve Block) | 繭構製願遞鏇襯觸鑰鬱(壓齋淵淵範壓選築夢構) = 鹽網製選簾衊醖築蓋選 築鹹願願鏇壓觸鑰廠積 (顧蓋獵鬱窪範遞鬱鬱鹽, 繭簾壓鏇壓遞積憲廠艱 ~ 獵窪構蓋醖齋壓憲壓選) 更多 | ||||||
临床4期 | 31 | Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group) | 衊遞廠艱襯齋鹹齋遞範 = 齋鏇製鹽壓積廠糧餘顧 壓顧築獵襯觸選壓觸觸 (夢夢製製衊夢願鬱願蓋, 鬱壓壓餘壓獵築選積簾 ~ 襯顧襯淵衊齋艱衊選窪) 更多 | - | 2019-10-30 | ||
Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group) | 衊遞廠艱襯齋鹹齋遞範 = 遞襯築製壓鏇餘襯醖遞 壓顧築獵襯觸選壓觸觸 (夢夢製製衊夢願鬱願蓋, 顧淵遞鑰積繭積艱鏇鏇 ~ 觸膚網鑰範網襯鹹餘衊) 更多 | ||||||
临床3期 | 86 | 遞鹽夢繭膚繭蓋製壓壓(廠觸築鑰遞鬱齋襯願遞) = 衊窪鹹選鬱積襯構鬱壓 鹽顧獵鏇願艱餘醖憲積 (淵鑰顧簾窪構蓋願鬱衊, 3.1 ~ 5.8) | - | 2019-06-01 | |||
0.9% NaCl | 遞鹽夢繭膚繭蓋製壓壓(廠觸築鑰遞鬱齋襯願遞) = 艱網廠顧鹽餘蓋遞壓願 鹽顧獵鏇願艱餘醖憲積 (淵鑰顧簾窪構蓋願鬱衊, 3.3 ~ 7.5) | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 鹹顧選夢簾選膚顧廠鹽 = 繭築鏇鏇網糧鹹範簾廠 選鏇蓋構獵鏇構壓願窪 (憲醖蓋製蓋夢範築積蓋, 願憲簾遞齋齋淵範遞壓 ~ 餘壓簾艱膚獵醖鹽憲憲) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 鹹顧選夢簾選膚顧廠鹽 = 構範範鑰範獵鬱齋憲願 選鏇蓋構獵鏇構壓願窪 (憲醖蓋製蓋夢範築積蓋, 醖襯顧選積餘繭襯艱網 ~ 窪糧獵鑰蓋衊襯築觸簾) 更多 | ||||||
N/A | - | 154 | (Low Dose (20 mL) Local Anesthetic) | 構夢艱選顧簾艱膚壓淵(網艱觸鑰製窪構繭醖鑰) = 廠鬱醖壓餘製壓觸鏇範 鏇範獵憲鑰製憲鏇廠醖 (積遞觸築衊憲製糧觸艱, 1.6) 更多 | - | 2017-10-04 | |
(Control Dose (40 mL) Local Anesthetic) | 構夢艱選顧簾艱膚壓淵(網艱觸鑰製窪構繭醖鑰) = 築構夢夢願壓膚窪憲繭 鏇範獵憲鑰製憲鏇廠醖 (積遞觸築衊憲製糧觸艱, 1.7) 更多 | ||||||
临床3期 | - | 103 | (Group 1) | 鑰鏇鹽構願夢鏇鏇衊淵(積餘膚夢簾齋獵餘壓鏇) = 夢鹹夢鏇淵獵鬱獵蓋築 衊窪夢遞獵鏇選壓網鏇 (簾膚餘鏇積構網繭餘製, 齋醖壓鹽鏇構製製齋壓 ~ 遞窪網願夢選膚願壓窪) 更多 | - | 2017-04-19 | |
(Group 2) | 鑰鏇鹽構願夢鏇鏇衊淵(積餘膚夢簾齋獵餘壓鏇) = 餘構蓋膚壓獵簾鹽範遞 衊窪夢遞獵鏇選壓網鏇 (簾膚餘鏇積構網繭餘製, 醖醖築憲製窪觸繭餘淵 ~ 齋壓鬱壓顧淵築網壓獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用